Q-omics provides the consensus-scored DNAJC17P1 profile across patient tissues and cancer cell-line models. DNAJC17P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DNAJC17P1 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, DNAJC17P1 RNA expression shows 7,024 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where DNAJC17P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC17P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC17P1 survival associations across molecular data types. DNAJC17P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC17P1 RNA expression–survival associations across cancer types. High DNAJC17P1 expression shows unfavorable associations in UVM, READ, KICH, THYM and SKCM, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DNAJC17P1 RNA expression.
This table summarizes DNAJC17P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJC17P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC17P1 shows higher tumor expression in COAD, BLCA, ESCA and KIRP. The COAD box plot shows higher DNAJC17P1 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p = .008).
This table shows molecular features associated with DNAJC17P1 in patient tissues and cancer cell lines. In patient samples, DNAJC17P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
